Show simple item record

dc.contributor.authorKlahn, Philipp
dc.contributor.authorFetz, Verena
dc.contributor.authorRitter, Antje
dc.contributor.authorCollisi, Wera
dc.contributor.authorHinkelmann, Bettina
dc.contributor.authorArnold, Tatjana
dc.contributor.authorTegge, Werner
dc.contributor.authorRox, Katharina
dc.contributor.authorHüttel, Stephan
dc.contributor.authorMohr, Kathrin I
dc.contributor.authorWink, Joachim
dc.contributor.authorStadler, Marc
dc.contributor.authorWissing, Josef
dc.contributor.authorJänsch, Lothar
dc.contributor.authorBrönstrup, Mark
dc.identifier.citationChem Sci. 2019 Apr 15;10(20):5197-5210. doi: 10.1039/c8sc05542d. eCollection 2019 May 28.en_US
dc.description.abstractThe concept of targeted drug conjugates has been successfully translated to clinical practice in oncology. Whereas the majority of cytotoxic effectors in drug conjugates are directed against either DNA or tubulin, our study aimed to validate nuclear export inhibition as a novel effector principle in drug conjugates. For this purpose, a semisynthetic route starting from the natural product ratjadone A, a potent nuclear export inhibitor, has been developed. The biological evaluation of ratjadones functionalized at the 16-position revealed that oxo- and amino-analogues had very high potencies against cancer cell lines (e.g. 16R-aminoratjadone 16 with IC50 = 260 pM against MCF-7 cells, or 19-oxoratjadone 14 with IC50 = 100 pM against A-549 cells). Mechanistically, the conjugates retained a nuclear export inhibitory activity through binding CRM1. To demonstrate a proof-of-principle for cellular targeting, folate- and luteinizing hormone releasing hormone (LHRH)-based carrier molecules were synthesized and coupled to aminoratjadones as well as fluorescein for cellular efficacy and imaging studies, respectively. The Trojan-Horse conjugates selectively addressed receptor-positive cell lines and were highly potent inhibitors of their proliferation. For example, the folate conjugate FA-7-Val-Cit-pABA-16R-aminoratjadone had an IC50 of 34.3 nM, and the LHRH conjugate d-Orn-Gose-Val-Cit-pABA-16R-aminoratjadone had an IC50 of 12.8 nM. The results demonstrate that nuclear export inhibition is a promising mode-of-action for extracellular-targeted drug conjugate payloads.en_US
dc.publisherRoyal Society of Chemistryen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.titleThe nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates.en_US
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalChemical Scienceen_US
dc.source.journaltitleChemical science

Files in this item

Klahn et al.pdf
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International